Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
Department of Pharmacy, Pharmacology and Postgraduate Medicine, University of Hertfordshire, College Lane, Hatfield AL10 9AB, UK.
Int J Pharm. 2018 Feb 5;536(2):570-581. doi: 10.1016/j.ijpharm.2017.08.088. Epub 2017 Aug 24.
The acceptability of pediatric pharmaceutical products to patients and their caregivers can have a profound impact on the resulting therapeutic outcome. However, existing methodology and approaches used for acceptability assessments for pediatric products is fragmented, making robust and consistent product evaluations difficult. A pediatric formulation development workshop took place in Washington, DC in June 2016 through the University of Maryland's Center of Excellence in Regulatory Science and Innovation (M-CERSI). A session at the workshop was dedicated to acceptability assessments and focused on two major elements that affect the overall acceptability of oral medicines, namely swallowability and palatability. The session started with presentations to provide an overview of literature, background and current state on swallowability and palatability assessments. Five parallel breakout discussions followed the presentations on each element, focusing on three overarching themes, risk-based approaches, methodology and product factors. This article reports the key outcomes of the workshop related to swallowability and palatability assessments.
儿科药物产品对患者及其照顾者的可接受性会对治疗结果产生深远影响。然而,现有的儿科产品可接受性评估方法和手段较为分散,使得产品评估难以做到稳健和一致。马里兰大学卓越监管科学与创新中心(M-CERSI)于 2016 年 6 月在华盛顿特区举办了儿科制剂开发研讨会。研讨会的一个环节专门用于可接受性评估,重点关注影响口服药物整体可接受性的两个主要因素,即可吞咽性和口感。该环节首先介绍了关于可吞咽性和口感评估的文献综述、背景和现状。在介绍完每个因素后,分成五个平行分组讨论,重点讨论三个总体主题,即基于风险的方法、方法和产品因素。本文报告了与可吞咽性和口感评估相关的研讨会的主要成果。